NASDAQ:LXRX Lexicon Pharmaceuticals (LXRX) Stock Price, News & Analysis → [BUY ALERT] Our #1 A.I. Stock for March (From Behind the Markets) (Ad) Free LXRX Stock Alerts $2.40 +0.21 (+9.59%) (As of 03/28/2024 ET) Add Compare Share Share Today's Range$2.13▼$2.4750-Day Range$1.30▼$3.5852-Week Range$0.92▼$3.79Volume7.06 million shsAverage Volume4.88 million shsMarket Capitalization$590.98 millionP/E RatioN/ADividend YieldN/APrice Target$5.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Lexicon Pharmaceuticals alerts: Email Address Lexicon Pharmaceuticals MarketRank™ Stock AnalysisAnalyst Rating0.00 Rating ScoreUpside/Downside108.3% Upside$5.00 Price TargetShort InterestBearish8.67% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.51Based on 5 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.71) to ($0.66) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.48 out of 5 starsMedical Sector894th out of 938 stocksPharmaceutical Preparations Industry403rd out of 425 stocks 2.0 Analyst's Opinion Price Target Upside/DownsideAccording to analysts' consensus price target of $5.00, Lexicon Pharmaceuticals has a forecasted upside of 108.3% from its current price of $2.40.Amount of Analyst CoverageLexicon Pharmaceuticals has received no research coverage in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted8.67% of the outstanding shares of Lexicon Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverLexicon Pharmaceuticals has a short interest ratio ("days to cover") of 4.6.Change versus previous monthShort interest in Lexicon Pharmaceuticals has recently increased by 1.33%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldLexicon Pharmaceuticals does not currently pay a dividend.Dividend GrowthLexicon Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for LXRX. Previous Next 1.9 News and Social Media Coverage News SentimentLexicon Pharmaceuticals has a news sentiment score of 0.51. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Lexicon Pharmaceuticals this week, compared to 2 articles on an average week.Search InterestOnly 27 people have searched for LXRX on MarketBeat in the last 30 days. This is a decrease of -58% compared to the previous 30 days.MarketBeat FollowsOnly 14 people have added Lexicon Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -42% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Lexicon Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 6.80% of the stock of Lexicon Pharmaceuticals is held by insiders.Percentage Held by Institutions74.70% of the stock of Lexicon Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Lexicon Pharmaceuticals are expected to grow in the coming year, from ($0.71) to ($0.66) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Lexicon Pharmaceuticals is -3.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Lexicon Pharmaceuticals is -3.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioLexicon Pharmaceuticals has a P/B Ratio of 3.87. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Gold Safe ExchangeTrump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.Protect your retirement savings from the inevitable devaluation of the dollar… About Lexicon Pharmaceuticals Stock (NASDAQ:LXRX)Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. The company has strategic collaboration and license agreements with Bristol-Myers Squibb Company, and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.Read More LXRX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart LXRX Stock News HeadlinesMarch 25, 2024 | globenewswire.comClinical Data on the Impact of Sotagliflozin on Stroke and Heart Attack Risk Among Four Lexicon-Sponsored Presentations at the American College of Cardiology 73rd Annual Scientific Session & ExpoMarch 24, 2024 | americanbankingnews.comLexicon Pharmaceuticals (NASDAQ:LXRX) Shares Down 5.8% March 28, 2024 | Gold Safe Exchange (Ad)Trump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.March 16, 2024 | finance.yahoo.comLXRX Apr 2024 5.000 putMarch 12, 2024 | seekingalpha.comLexicon stock slides 8% after rallying 30% in prior sessionMarch 12, 2024 | markets.businessinsider.comLexicon Announces Positive Data Of InTandem3 Study In Type 1 Diabetes Patients With CKD; Stock DownMarch 12, 2024 | finance.yahoo.comNew Post Hoc Analysis of inTandem3 Study Demonstrates Improvements In Glycemic Control With Sotagliflozin Treatment in Patients With Type 1 Diabetes and Chronic Kidney DiseaseMarch 12, 2024 | seekingalpha.comLexicon Pharmaceuticals: Moving To Maximize The Value Of Its Core AssetMarch 28, 2024 | Gold Safe Exchange (Ad)Trump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.March 11, 2024 | marketwatch.comLexicon Pharmaceuticals Shares Rise on Beat to 4Q Loss, Plans for SotagliflozinMarch 11, 2024 | finance.yahoo.comLexicon Preparing to Resubmit Sotagliflozin NDA for Type 1 Diabetes Following Feedback From FDAMarch 11, 2024 | washingtonpost.comLexicon: Q4 Earnings SnapshotMarch 11, 2024 | benzinga.comLexicon Pharmaceuticals: Q4 Earnings InsightsMarch 11, 2024 | globenewswire.comLexicon Pharmaceuticals Reports Fourth Quarter 2023 Financial Results and Provides Business UpdateMarch 11, 2024 | globenewswire.comLexicon Announces Oversubscribed $250 Million Private Placement of Equity SecuritiesFebruary 22, 2024 | finance.yahoo.com15 Hot Penny Stocks On the MoveFebruary 17, 2024 | finance.yahoo.comLXRX Feb 2024 5.000 putJanuary 31, 2024 | fool.com3 Under-the-Radar Stocks With 340% to 762% Upside in 2024, According to Select Wall Street AnalystsJanuary 26, 2024 | seekingalpha.comLexicon Pharmaceuticals Putting The Pieces Together, But Much Is Left To DoJanuary 11, 2024 | finance.yahoo.comLexicon Pharmaceuticals, Inc.'s (NASDAQ:LXRX) largest shareholders are private equity firms with 48% ownership, institutions own 24%January 8, 2024 | finance.yahoo.comLexicon Pharmaceuticals Provides Business and Pipeline Update at 42nd Annual J.P. Morgan Healthcare ConferenceJanuary 4, 2024 | seekingalpha.comLexicon Pharma: Inpefa's Early Clinical Benefits, Rehospitalization Data May Unlock Significant ValueDecember 26, 2023 | fool.com3 Growth Stocks Expected to Skyrocket in 2024, According to Wall StreetDecember 21, 2023 | finance.yahoo.comLexicon Pharmaceuticals To Participate In The 42nd Annual JPMorgan Healthcare ConferenceDecember 13, 2023 | finance.yahoo.comMSCLF: AAK1 Disclosed as Drug Target for DMD Program…November 24, 2023 | bizjournals.comThe Woodlands at 50November 22, 2023 | finance.yahoo.comLexicon Pharmaceuticals to Participate in the 35th Annual Piper Sandler Healthcare Conference and the 6th Annual Evercore ISI HealthCONx ConferenceSee More Headlines Receive LXRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Lexicon Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/03/2021Today3/28/2024Next Earnings (Estimated)5/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:LXRX Previous SymbolNASDAQ:LEXG CUSIP52887210 CIK1062822 Webwww.lexpharma.com Phone(281) 863-3000Fax281-863-8010Employees135Year Founded1995Price Target and Rating Average Stock Price Target$5.00 High Stock Price Target$5.00 Low Stock Price Target$5.00 Potential Upside/Downside+108.3%Consensus Rating Rating Score (0-4)0.00 Research Coverage0 Analysts Profitability EPS (Most Recent Fiscal Year)($0.80) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-175,610,000.00 Net Margins-14,573.20% Pretax Margin-14,710.88% Return on Equity-138.54% Return on Assets-71.29% Debt Debt-to-Equity Ratio1.07 Current Ratio5.60 Quick Ratio6.91 Sales & Book Value Annual Sales$1.20 million Price / Sales492.48 Cash FlowN/A Price / Cash FlowN/A Book Value$0.62 per share Price / Book3.87Miscellaneous Outstanding Shares246,240,000Free Float228,270,000Market Cap$590.98 million OptionableOptionable Beta1.28 Social Links Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesMr. Lonnel Coats (Age 59)CEO & Director Comp: $1.22MMr. Jeffrey L. Wade J.D. (Age 59)President & CFO Comp: $788.65kMr. Brian T. Crum (Age 50)Senior VP, General Counsel & Secretary Comp: $609.1kDr. Kenneth B. Kassler-Taub M.D. (Age 67)Senior Vice President of Regulatory Affairs & Quality Assurance Comp: $588.7kDr. Craig B. Granowitz M.D. (Age 58)Ph.D., Senior VP & Chief Medical Officer Comp: $671.14kDr. Robert J. Lefkowitz M.D. (Age 80)Consultant & Independent Director Comp: $50kMs. Kristen L. Alexander (Age 55)Vice President of Finance & Accounting Ms. Lisa M. DeFrancesco (Age 44)Head of Investor Relations & Corporate Strategy Chas SchultzExecutive Director of Corporate Communications & Patient AdvocacyMs. Wendy E. McDermott (Age 52)Vice President of Human Resources More ExecutivesKey CompetitorsAVEO PharmaceuticalsNASDAQ:AVEOVerastemNASDAQ:VSTMXOMANASDAQ:XOMAOPKO HealthNASDAQ:OPKRigel PharmaceuticalsNASDAQ:RIGLView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Sold 419,840 shares on 3/11/2024Ownership: 2.442%Goldman Sachs Group Inc.Sold 124,372 shares on 3/1/2024Ownership: 0.096%GSA Capital Partners LLPBought 780,077 shares on 2/16/2024Ownership: 0.318%Citadel Advisors LLCBought 2,700 shares on 2/15/2024Ownership: 0.000%Wolverine Trading LLCSold 1,100 shares on 2/15/2024Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions LXRX Stock Analysis - Frequently Asked Questions What is Lexicon Pharmaceuticals' stock price target for 2024? 0 analysts have issued twelve-month price targets for Lexicon Pharmaceuticals' shares. Their LXRX share price targets range from $5.00 to $5.00. On average, they anticipate the company's share price to reach $5.00 in the next year. This suggests a possible upside of 108.3% from the stock's current price. View analysts price targets for LXRX or view top-rated stocks among Wall Street analysts. How have LXRX shares performed in 2024? Lexicon Pharmaceuticals' stock was trading at $1.53 at the beginning of the year. Since then, LXRX shares have increased by 56.9% and is now trading at $2.40. View the best growth stocks for 2024 here. When is Lexicon Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 7th 2024. View our LXRX earnings forecast. How were Lexicon Pharmaceuticals' earnings last quarter? Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) announced its quarterly earnings data on Wednesday, November, 3rd. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, topping the consensus estimate of ($0.18) by $0.02. The biopharmaceutical company had revenue of $0.02 million for the quarter. Lexicon Pharmaceuticals had a negative net margin of 14,573.20% and a negative trailing twelve-month return on equity of 138.54%. During the same quarter in the prior year, the firm earned $0.71 earnings per share. What is Lonnel Coats' approval rating as Lexicon Pharmaceuticals' CEO? 9 employees have rated Lexicon Pharmaceuticals Chief Executive Officer Lonnel Coats on Glassdoor.com. Lonnel Coats has an approval rating of 100% among the company's employees. This puts Lonnel Coats in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Lexicon Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Lexicon Pharmaceuticals investors own include Portola Pharmaceuticals (PTLA), Sarepta Therapeutics (SRPT), ACADIA Pharmaceuticals (ACAD), Dynavax Technologies (DVAX), MannKind (MNKD), ImmunoGen (IMGN), Geron (GERN), Micron Technology (MU), TherapeuticsMD (TXMD) and Gilead Sciences (GILD). Who are Lexicon Pharmaceuticals' major shareholders? Lexicon Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional shareholders include BVF Inc. IL (9.98%), Vanguard Group Inc. (2.44%), Vanguard Group Inc. (2.44%), Pinnacle Associates Ltd. (0.71%), Charles Schwab Investment Management Inc. (0.35%) and Northern Trust Corp (0.35%). Insiders that own company stock include International SCA Artal, Jeffrey L Wade, Lonnel Coats, Raymond Debbane and Wendy Mcdermott. View institutional ownership trends. How do I buy shares of Lexicon Pharmaceuticals? Shares of LXRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:LXRX) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeGrab Your Free Bitcoin Today!Crypto Swap ProfitsMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceTop Project Outperforms BTC in 2023…Crypto 101 MediaForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill Publishing“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryFed launches fourth dollar overhaulStansberry ResearchBREAKING: New AI Breakthrough Could Change Healthcare ForeverBehind the Markets Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lexicon Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.